Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)
Hong Kong · Delayed Price · Currency is HKD 5.42
-0.18 (-3.22%)
Sep 18, 2026, 3:41 PM HKT
HKG:2566 Revenue
Hangzhou Jiuyuan Genetic Biopharmaceutical had revenue of 630.95M CNY in the half year ending June 30, 2026, a decrease of -10.17%. This brings the company's revenue in the last twelve months to 1.30B, down -0.55% year-over-year. In the year 2025, Hangzhou Jiuyuan Genetic Biopharmaceutical had annual revenue of 1.31B, down -4.59%.
Revenue (ttm)
1.30B CNY
Revenue Growth
-0.55%
P/S Ratio
0.87
Revenue / Employee
726.62K CNY
Employees
1,787
Market Cap
1.30B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31B | -62.88M | -4.59% |
| Dec 31, 2024 | 1.37B | 81.78M | 6.35% |
| Dec 31, 2023 | 1.29B | 162.00M | 14.40% |
| Dec 31, 2022 | 1.13B | -181.85M | -13.91% |
| Dec 31, 2021 | 1.31B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Mabpharm | 888.77M |
| Shandong Boan Biotechnology | 720.87M |
| Guangzhou Innogen Pharmaceutical Group | 176.96M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 170.32M |
| CANbridge Pharmaceuticals | 64.28M |
| Beijing Biostar Pharmaceuticals | 63.74M |
| Zhaoke Ophthalmology | 40.41M |
| SinoMab BioScience | 6.28M |